Clinical Trial

Multimodal Deep Learning for Lymph Node Metastasis in Thyroid Cancer

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 23, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy in clinical practice, accounting for approximately 85% of all thyroid malignancies. The occurrence of cervical lymph node metastasis further increases the risk of local tumor recurrence and distant metastasis, thereby reducing patient survival rates. Pathological examinations reveal that approximately 30-80% of PTC patients have lymph node metastasis. Early detection of metastatic lymph nodes and the development of individualized treatment plans are crucial for improving patient prognosis. Currently, the primary method for diagnosing lymph node metastasis is ultrasound-guided fine-needle aspiration, but its accuracy is limited by sample quality and carries a risk of false-negative results. In recent years, deep learning technology has demonstrated significant potential in the field of medical image analysis. Therefore, the investigators aim to develop a deep learning model based on neck ultrasound to more accurately predict lymph node metastasis.
Trial Details
NCT Number NCT07299318
Lead Sponsor West China Hospital
Conditions Papillary Thyroid Carcinoma
Enrollment 3,200 participants
Start Date 2026-01-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-05-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-23